(NASDAQ: LGVN) Longeveron's forecast annual revenue growth rate of 258.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.36%.
Longeveron's revenue in 2026 is $1,216,000.On average, 6 Wall Street analysts forecast LGVN's revenue for 2026 to be $47,467,018, with the lowest LGVN revenue forecast at $18,863,468, and the highest LGVN revenue forecast at $81,759,135. On average, 6 Wall Street analysts forecast LGVN's revenue for 2027 to be $199,367,703, with the lowest LGVN revenue forecast at $122,094, and the highest LGVN revenue forecast at $710,697,118.
In 2028, LGVN is forecast to generate $1,284,381,499 in revenue, with the lowest revenue forecast at $45,785,115 and the highest revenue forecast at $2,595,268,531.